Following treatment with a proteasome inhibitor MG132, the accumulation of endogenous PRMT5 in cells overexpressing LINC01138 was greater (Fig. 4c and Supplementary Fig. 8h), indicating that LINC01138 might inhibit the proteasome-dependent degradation of PRMT5 in HCC cells. Here, LINC01138 is linked to hepatocellular carcinoma.